Developer of human microbiome therapeutics designed to treat diseases of tissue barrier deficiency. The company's microbiome therapeutic treatments engage the body's immune system to treat a broad range of pathogens in biofilm form, and the company's discovery platform allows the discovery effort to focus on high therapeutic yield and target organ-relevant, safe and scalable therapeutics, enabling physicians to better solve the problem of antibiotic resistance.